,,,looks like the probablity of RVX actually acheiving getting these additional trials started by end  of H2 as indicated in their latest presentation is most likely just a pipe dream! Well out of line as to timing if the top line results are in the 4th quarter with data having to be analysed in order to formulate the trial designs. Not that the inability to forecast timing and costs are un-expected from our management team. It is the absolute norm and should be expected!! ,,, it becomes sort of a soap opera after withnessing so many missed milestones,,especuially this BoM trial timing.

Lack of clarity and the previously mentioned issue is possibly the driving force around the lack luster share price this late in the trial. The unknown is not only relegated to us minions,,,our management team has no handle on such important basics as timing and costs, and the Market knows it! If it walks like a duck and quacks like a duck it most likely is a duck!!!!..However,,,..being the eternal optimist that I am,,,I will continue to think that the exceeeeeedingly good trial data announced from the BoM trial will negate the rush for addtitonal trial starts in 2019,,,,!! ......jmo